Ignite Creation Date:
2024-05-05 @ 6:33 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00506298
Status:
COMPLETED
Last Update Posted:
2009-05-13
First Post:
2007-07-20
Brief Title:
Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes
Sponsor:
Zalicus
Organization:
Zalicus
Study Overview
Official Title:
A Randomized Multi-Center Study to Compare the Effects of CRx-401 to Bezafibrate Plus Placebo on Plasma Glucose Levels When Given to Subjects With Type II Diabetes on Metformin
Status:
COMPLETED
Status Verified Date:
2009-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will assess the efficacy of CRx-401 in lowering FPG levels in patients taking metformin to treat their diabetes In addition this initial trial will evaluate insulin resistance HOMA-IR index HgbA1c levels glycated protein LDL HDL triglycerides and total cholesterol as well as the safety of CRx-401
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None